At a glance
ClinicalIndex Comparison RecordN/ACompleted· 2 enrolled
Drug / intervention
Efavirenz +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Randomized Study to Determine the Impact of Antiretroviral Treatment in HCV/HIV-Coinfected Subjects With High CD4+ Cell Count on the Efficacy of Hepatitis C Treatment With Pegylated Interferon Alfa-2A and Ribavirin
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Jan 4, 2005·Updated Nov 1, 2021
In Brief
A clinical study evaluating Efavirenz, Lamivudine, and 4 other interventions for HIV Infections and Hepatitis C. Completed, enrolled 2 participants across 2 sites.
Detailed Summary
A significant proportion of HIV infected people in the U.S. are also infected with hepatitis C virus (HCV). The purpose of this study is to determine the effects of anti-HIV therapy on treatment of HCV with pegylated interferon alfa-2a and ribavirin (PEG/RBV).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections, Hepatitis C
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2005
Study CompletionJan 2007
TodayJul 2026
First PostedJan 4, 2005
Study CompletionJan 1, 2007
TodayJul 2, 2026
Posted 21.5 years ago
Interventions
Efavirenzdrug
Lamivudinedrug
Lopinavir/ritonavirdrug
Pegylated interferon alfa-2adrug
Ribavirindrug
Tenofovir disoproxil fumaratedrug